Profile data is unavailable for this security.
About the company
Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.
- Revenue in SEK (TTM)0.00
- Net income in SEK-280.03m
- Incorporated2009
- Employees22.00
- LocationCantargia ABScheelevagen 27LUND 223 63SwedenSWE
- Phone+46 462756260
- Websitehttps://cantargia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mendus AB (publ) | 0.00 | -101.62m | 452.23m | 30.00 | -- | 0.5499 | -- | -- | -0.2554 | -0.2554 | 0.00 | 0.8165 | 0.00 | -- | -- | 0.00 | -14.77 | -18.84 | -15.78 | -20.21 | -- | -- | -- | -28,474.53 | -- | -- | 0.0325 | -- | -100.00 | -- | 26.78 | -- | -- | -- |
| Initiator Pharma A/S | 0.00 | -35.69m | 478.89m | 2.00 | -- | 27.27 | -- | -- | -0.6567 | -0.6567 | 0.00 | 0.3319 | 0.00 | -- | -- | 0.00 | -58.55 | -65.10 | -62.50 | -70.59 | -- | -- | -- | -- | -- | -- | 0.5804 | -- | -- | -- | 40.52 | -- | -- | -- |
| Promimic AB | 37.07m | -9.22m | 481.36m | 17.00 | -- | 6.27 | -- | 12.99 | -0.5283 | -0.5283 | 2.08 | 4.11 | 0.3994 | -5.63 | 3.00 | 2,180,588.00 | -9.93 | -24.89 | -11.67 | -29.25 | 103.90 | 101.23 | -24.88 | -89.47 | 3.98 | -- | 0.00 | -- | 128.63 | -- | 41.95 | -- | -- | -- |
| Bergenbio ASA | 354.40k | -190.62m | 511.05m | 18.00 | -- | 2.75 | -- | 1,442.03 | -0.2647 | -0.2647 | 0.0002 | 0.0474 | 0.0021 | -- | -- | -- | -111.66 | -66.15 | -176.09 | -78.74 | -- | -- | -53,785.59 | -11,419.44 | -- | -- | 0.00 | -- | -9.00 | -31.43 | 36.98 | -- | -- | -- |
| Hamlet BioPharma AB | 0.00 | -26.59m | 520.00m | 7.00 | -- | 11.49 | -- | -- | -0.207 | -0.207 | 0.00 | 0.3543 | 0.00 | -- | -- | -- | -63.29 | -83.52 | -69.05 | -107.84 | -- | -- | -- | -- | -- | -- | 0.0984 | -- | -- | -- | -18.87 | -- | 78.01 | -- |
| Enzymatica AB (publ) | 47.29m | -53.67m | 554.82m | 18.00 | -- | 6.61 | -- | 11.73 | -0.3247 | -0.3247 | 0.2866 | 0.4841 | 0.3269 | 1.38 | 6.48 | -- | -37.11 | -27.36 | -39.16 | -33.98 | 64.25 | 65.08 | -113.50 | -66.12 | -- | -23.26 | 0.2502 | -- | 4.00 | -0.6382 | 27.57 | -- | 7.02 | -- |
| Gentian Diagnostics ASA | 142.38m | -5.84m | 586.71m | 58.00 | -- | 3.87 | 163.70 | 4.12 | -0.3783 | -0.3783 | 9.22 | 9.82 | 0.7646 | 1.85 | 6.35 | 2,452,035.00 | -3.14 | -10.76 | -3.58 | -11.86 | 50.84 | 41.46 | -4.10 | -26.99 | 4.14 | -- | 0.0555 | -- | 32.98 | 27.63 | 54.92 | -- | -4.92 | -- |
| Oncopeptides AB | 35.22m | -249.11m | 610.92m | 57.00 | -- | 6.47 | -- | 17.35 | -1.96 | -1.96 | 0.2776 | 0.4474 | 0.1129 | -- | 1.44 | 617,894.80 | -79.88 | -141.28 | -101.04 | -200.49 | 103.06 | -- | -707.30 | -2,689.06 | -- | -- | 0.7065 | -- | 321.54 | -- | 26.29 | -- | -- | -- |
| Cantargia AB | 0.00 | -280.03m | 671.56m | 22.00 | -- | 3.98 | -- | -- | -1.65 | -1.65 | 0.00 | 0.9186 | 0.00 | -- | -- | 0.00 | -80.18 | -55.08 | -100.27 | -61.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.69 | -- | -- | -- |
| Intellego Technologies AB | 186.49m | 59.60m | 691.76m | 62.00 | 11.26 | 4.57 | 10.96 | 3.71 | 2.33 | 2.33 | 7.35 | 5.74 | 0.8841 | 3.87 | 3.69 | 3,007,968.00 | 28.26 | -- | 44.00 | -- | 68.73 | -- | 31.96 | -- | 2.07 | 5.82 | 0.1684 | -- | 222.74 | -- | 493.56 | -- | -- | -- |
| Alligator Bioscience AB | 55.49m | -248.80m | 692.09m | 55.00 | -- | -- | -- | 12.47 | -0.4848 | -0.4848 | 0.0999 | -0.0772 | 0.5289 | -- | 8.07 | 956,741.40 | -237.13 | -73.26 | -- | -91.33 | -- | -- | -448.35 | -811.68 | -- | -104.20 | -- | -- | 62.78 | 16.60 | -28.53 | -- | -20.34 | -- |
| Orexo AB | 619.10m | -73.40m | 711.57m | 113.00 | -- | 11.50 | 122.68 | 1.15 | -2.13 | -2.13 | 17.98 | 1.78 | 0.6959 | 1.08 | 2.53 | 5,337,069.00 | -8.25 | -6.41 | -20.27 | -9.99 | 88.14 | 86.76 | -11.86 | -11.83 | 0.589 | 0.1386 | 0.8948 | -- | 2.32 | -3.99 | 27.76 | -- | 25.77 | -- |
| Nightingale Health Oyj | 42.55m | -210.28m | 730.95m | 81.00 | -- | 1.07 | -- | 17.18 | -0.2979 | -0.2979 | 0.0603 | 1.50 | 0.0344 | 1.60 | 3.87 | 44,560.98 | -17.02 | -14.20 | -18.12 | -15.69 | 75.81 | 83.57 | -494.25 | -408.50 | 14.15 | -- | 0.0378 | -- | 80.80 | 19.05 | -12.38 | -- | -- | -- |
| IRLAB Therapeutics AB | 5.68m | -157.30m | 763.88m | 28.00 | -- | 9.97 | -- | 134.53 | -3.03 | -3.03 | 0.1095 | 1.48 | 0.0274 | -- | 0.4652 | 218,384.60 | -75.97 | -27.12 | -94.23 | -30.42 | -1,952.47 | -72.18 | -2,770.38 | -155.57 | -- | -- | 0.2646 | -- | -90.71 | 216.07 | -56.82 | -- | -22.56 | -- |
| Moberg Pharma AB (publ) | 0.00 | -21.09m | 775.52m | -- | -- | 1.25 | -- | -- | -1.20 | -1.20 | 0.00 | 21.84 | 0.00 | -- | -- | -- | -3.52 | -- | -3.66 | -- | -- | -- | -- | -- | 3.04 | -- | 0.0077 | -- | -100.00 | -- | -34.26 | -- | -- | -- |
Data as of May 17 2024. Currency figures normalised to Cantargia AB's reporting currency: Swedish Krona SEK
24.84%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 30 Jun 2023 | 14.74m | 8.03% |
| F�rsta AP-fondenas of 30 Jun 2023 | 10.54m | 5.74% |
| Alecta Pension Insurance Mutualas of 30 Jun 2023 | 10.10m | 5.50% |
| Handelsbanken Fonder ABas of 30 Apr 2024 | 4.82m | 2.63% |
| Swedbank Robur Fonder ABas of 29 Feb 2024 | 3.69m | 2.01% |
| SEB Investment Management ABas of 30 Apr 2024 | 1.01m | 0.55% |
| SSgA Funds Management, Inc.as of 04 Apr 2024 | 352.01k | 0.19% |
| Alfred Berg Kapitalforvaltning ASas of 30 Jun 2023 | 160.18k | 0.09% |
| Skandia Investment Management ABas of 29 Feb 2024 | 113.71k | 0.06% |
| Storebrand Asset Management ASas of 31 Jan 2024 | 88.76k | 0.05% |
More ▼
Data from 31 Dec 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
